AstraZeneca Gains US OK For Fasenra In Patient-Friendly Form
Levels playing field with GSK's Nucala
Executive Summary
The company is keeping up the pressure on GSK, getting approval for self-administration for Fasenra a few months after a similar green light for severe asthma rival Nucala.